LUMO / Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates

AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidat more_horizontal

Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Lisa Miller – Senior Director of I more_horizontal

Lumos Pharma (LUMO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of more_horizontal

Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold cl more_horizontal

Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues t more_horizontal

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics more_horizontal

Lumos Pharma, Inc. (NASDAQ:LUMO ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director, IR Rich more_horizontal

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q4 2021 Results - Earnings Call Transcript more_horizontal